Bond Biosciences is focused on developing innovative non-absorbed oral therapeutics aimed at treating ion-related diseases, particularly hereditary hemochromatosis (HH). Their lead product, BBI-001, is designed to bind excess dietary iron in the gastrointestinal tract, thereby preventing its absorption. This approach addresses the unmet medical need for effective treatments for HH, a genetic disorder that leads to iron overload and can result in severe health complications such as liver disease, heart issues, and joint pain. Unlike traditional phlebotomy, which is often burdensome and poorly adhered to by patients, BBI-001 offers a more convenient oral alternative that has shown promise in pre-clinical studies and is currently advancing towards clinical trials.

In addition to BBI-001, Bond Biosciences is exploring the potential of non-absorbed polymers for the treatment and prevention of other ion-related diseases. The company recognizes the limitations of existing therapies, such as the need for frequent phlebotomies, which can lead to patient non-compliance and increased health risks. By focusing on the development of oral maintenance therapies, Bond aims to improve patient adherence and health outcomes, potentially reducing or eliminating the reliance on phlebotomy for managing iron levels in patients with hereditary hemochromatosis.

United States

Bond Biosciences, Inc. is a privately held, clinical stage biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease.

Bond Biosciences

Company Details